CALTX.ST
Price:
$208
Market Cap:
$11.24B
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis,...[Read more]
Industry
Biotechnology
IPO Date
2018-06-29
Stock Exchange
STO
Ticker
CALTX.ST
According to Calliditas Therapeutics AB (publ)’s latest financial reports and current stock price. The company's current ROE is -210.18%. This represents a change of 177.84% compared to the average of -75.65% of the last 4 quarters.
The mean historical ROE of Calliditas Therapeutics AB (publ) over the last ten years is -49.85%. The current -210.18% ROE has changed 321.62% with respect to the historical average. Over the past ten years (40 quarters), CALTX.ST's ROE was at its highest in in the March 2017 quarter at 82.68%. The ROE was at its lowest in in the June 2018 quarter at -248.02%.
Average
-49.85%
Median
-50.54%
Minimum
-282.05%
Maximum
400.14%
Discovering the peaks and valleys of Calliditas Therapeutics AB (publ) ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 772.32%
Maximum Annual ROE = 400.14%
Minimum Annual Increase = -241.87%
Minimum Annual ROE = -282.05%
Year | ROE | Change |
---|---|---|
2023 | -139.24% | 158.80% |
2022 | -53.80% | 6.47% |
2021 | -50.54% | 40.14% |
2020 | -36.06% | 772.32% |
2019 | -4.13% | -80.65% |
2018 | -21.36% | -91.83% |
2017 | -261.62% | -165.38% |
2016 | 400.14% | -241.87% |
The current ROE of Calliditas Therapeutics AB (publ) (CALTX.ST) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-81.19%
5-year avg
-56.75%
10-year avg
-49.85%
Calliditas Therapeutics AB (publ)’s ROE is greater than Oncopeptides AB (publ) (-280.43%), greater than BioArctic AB (publ) (-8.62%), less than Hansa Biopharma AB (publ) (242.32%), less than Camurus AB (publ) (10.44%), less than Bonesupport Holding AB (publ) (15.03%),
Company | ROE | Market cap |
---|---|---|
-280.43% | $438.37M | |
-8.62% | $12.56B | |
242.32% | $2.19B | |
10.44% | $35.23B | |
15.03% | $22.46B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Calliditas Therapeutics AB (publ) using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Calliditas Therapeutics AB (publ) or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Calliditas Therapeutics AB (publ)'s ROE?
How is the ROE calculated for Calliditas Therapeutics AB (publ) (CALTX.ST)?
What is the highest ROE for Calliditas Therapeutics AB (publ) (CALTX.ST)?
What is the 3-year average ROE for Calliditas Therapeutics AB (publ) (CALTX.ST)?
What is the 5-year average ROE for Calliditas Therapeutics AB (publ) (CALTX.ST)?
How does the current ROE for Calliditas Therapeutics AB (publ) (CALTX.ST) compare to its historical average?